Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instability

Blood

Volumn 111, Issue 9, 2008, Pages 4700-4705

  Bochtler, Tilmann ^a   Hegenbart, Ute ^a   Cremer, Friedrich W ^b   Heiss, Christiane ^a,c   Benner, Axel ^c   Hose, Dirk ^a,c   Moos, Marion ^a   Bila, Jelena ^b   Bartram, Claus R ^b   Ho, Anthony D ^a   Goldschmidt, Hartmut ^a,c   Jauch, Anna ^b   Schonland, Stefan O ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN;

ADULT; AGED; AMYLOIDOSIS; ARTICLE; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HEMATOLOGICAL PARAMETERS; HUMAN; KARYOTYPING; MAJOR CLINICAL STUDY; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; PRIORITY JOURNAL; COHORT ANALYSIS; GENETICS; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; AMYLOIDOSIS; CHROMOSOME ABERRATIONS; COHORT STUDIES; FEMALE; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; MONOCLONAL GAMMOPATHIES, BENIGN;

EID: 47149110690     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-11-122101     Document Type: Article

References (47)

1. Sanchorawala V. Blanchard E, Seldin DC. O'Hara C, Skinner M, Wright DG. AL amyloidosis associated with B-cell lymphoproliterative disorders: frequency and treatment outcomes. Am J Hematol. 2006;81:692-695.
2. Comenzo RL, Zhang Y, Martinez C, Osman K. Herrera GA. The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burden. Blood. 2001; 98:714-720.
3. Perfetti V. Casarini S, Palladini G. et al. Analysis of V(lambda)-J(lambda) expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r (lambdalll) as a new amyloid-associated germline gene segment. Blood. 2002;100:948-953.
4. Abraham RS, Geyer SM, Price-Troska TL, et al. Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL). Blood. 2003;101:3801-3808.
5. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003;349:583-596.
6. Fonseca R. Ahmann GJ, Jalal SM. et al. Chromosomal abnormalities in systemic amyloidosis. Br J Haematol. 1998;103:704-710.
7. Harrison CJ, Mazzullo H, Ross FM, et al. Translocations of 14q32 and deletions of 13q14 are common chromosomal abnormalities in systemic amyloidosis. Br J Haematol. 2002;117:427-435.
8. Hayman SR, Bailey RJ, Jalal SM, et al. Translocations involving the immunoglobulin heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosis. Blood. 2001; 98:2266-2268.
9. Perfetti V. Coluccia AM, Intini D, et al. Translocation T(4;14)(p16.3;q32) is a recurrent genetic lesion in primary amyloidosis. Am J Pathol. 2001; 158:1599-1603.
10. Chng WJ, Van Wier SA, Ahmann GJ, et al. A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS. Blood. 2005;106:2156-2161.
11. Fonseca R. Debes-Marun CS. Picken EB, et al. The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood. 2003;102:2562-2567.
12. Smadja NV, Fruchart C, Isnard F, et al. Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases. Leukemia. 1998:12:960-969.
13. Wuilleme S, Robillard N, Lode L, et al. Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma. Leukemia. 2005:19:275-278.
14. Lai JL, Zandecki M, Mary JY, et al. Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis. Blood. 1995;85:2490-2497.
15. Cremer FW, Bila J, Buck I, etal. Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics. Genes Ghromosomes Cancer. 2005;44:194-203.
16. Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined significance. Br J Haematol. 2006;134:573-589.
17. Avet-Loiseau H, Facon T, Daviet A, et al. 14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma: Intergroupe Francophone du Myelome. Cancer Res. 1999:59:4546-4550.
18. Fonseca R, Bailey RJ, Ahmann GJ, et al. Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood. 2002:100:1417-1424.
19. Fonseca R, Barlogie B, Bataille R, et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res. 2004;64:1546-1558.
20. Durie BG. Staging and kinetics of multiple myeloma. Semin Oncol. 1986;13:300-309.
21. Skinner M, Sanchorawala V, Seldin DC, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med. 2004:140:85-93.
22. Gertz MA. Amyloidosis: recognition, prognosis, and conventional therapy. Hematology. 1999;339-347.
23. Bochtler T, Hegenbart U, Heiss C, et al. Evaluation of the serum-free light chain test in untreated patients with ALamyloidosis. Haematologica. 2008:93:459-462.
24. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat. 1979;6:65-70.
25. von Heydebreck A, Gunawan B, Fuzesi L. Maximum likelihood estimation of oncogenetic tree models. Biostatistics. 2004;5:545-556.
26. Felsenstein J. Confidence limits on phylogenies: an approach using the bootstrap. Evolution. 1985;39:783-791.
27. R Development Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2007.
28. Avet-Loiseau H, Attal M, Moreau P, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood. 2007:109:3489-3495.
29. Cremer FW, Kartal M, Hose D, et al. High incidence and intraclonal heterogeneity of chromosome 11 aberrations in patients with newly diagnosed multiple myeloma detected by multiprobe interphase FISH. Cancer Genet Cytogenet. 2005; 161:116-124.
30. Fonseca R, Blood EA, Oken MM, et al. Myeloma and the t(11;14)(q13:q32): evidence for a biologically defined unique subset of patients. Blood. 2002;99:3735-3741.
31. Gertz MA, Lacy MQ, Dispenzieri A, et al. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3; q32), and-17p13 in myeloma patients treated with high-dose therapy. Blood. 2005;106:2837-2840.
32. Gutierrez NC, Castellanos MV, Martin ML, et al. Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis. Leukemia. 2007;21:143-150.
33. Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J Jr. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood. 2005;106:296-303.
34. Specht K, Haralambieva E, Bink K, et al. Different mechanisms of cyclin D1 overexpression in multiple myeloma revealed by fluorescence in situ hybridization and quantitative analysis of mRNA levels. Blood. 2004;104:1120-1126.
35. Avet-Loiseau H, Facon T, Grosbois B, et al. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood. 2002;99:2185-2191.
36. Avet-Loiseau H, Garand R, Lode L, Harousseau JL, Bataille R. Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants. Blood. 2003; 101:1570-1571.
37. Stilgenbauer S, Liebisch P, James MR, et al. Molecular cytogenetic delineation of a novel critical genomic region in chromosome bands 11q22.3-923.1 in lymphoproliferative disorders. Proc Natl Acad Sci U S A. 1996;93:11837-11841.
38. Keats JJ, Reirnan T, Maxwell CA, et al. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood. 2003;101:1520-1529.
39. Fonseca R, Van Wier SA, Chng WJ, et al. Prognostic value of chromosome 1 q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. Leukemia. 2006;20:2034-2040.
40. Hanamura I, Stewart JP, Huang Y, et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stemcell transplantation. Blood. 2006;108:1724-1732.
41. Sawyer JR, Tricot G, Mattox S, Jagannath S, Barlogie B. Jumping translocations of chromosome 1q in multiple myeloma: evidence for a mechanism involving decondensation of pericentromeric heterochromatin. Blood. 1998;91:1732-1741.
42. Bryce A, Ketterling R, Gertz M, et al. 14q32 abnormalities and 13q deletions are common in primary systemic amyloidosis using cytoplasmic immunoglobulin fluorescence in situ hybridization (clg-FISH) [abstract]. Blood. 2007;110. Abstract 2477.
43. Drach J, Ackermann J, Fritz E, et al. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood. 1998;92:802-809.
44. Jaksic W, Trudel S, Chang H, et al. Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance. J Clin Oncol. 2005;23:7069-7073.
45. Stewart AK, Bergsagel PL, Greipp PR, et al. A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia. 2007;21:529-534.
46. Bochtler T, Schonland SO, Cremer F, et al. The translocation t(M; 14) is frequently detected in patients with ALamyloidosis. In: Xlth International Symposium on Amyloidosis. London, United Kingdom: CRC Press; 2008, pp 228-230.
47. Bochtler T, Schonland SO, Jauch A, et al. Evaluation of cytogenetic aberration pattern in AL amyloidosis compared to monoclonal gammopathies not requiring treatment: Translocation t(M;14) is more frequent in ALamyloidosis [abstract]. Blood. 2007;110. Abstract 2500.